Drug intelligence / Profile preview

EG011

Development stage: Preclinical
Lead developer: Foundation for the Institute of Oncology Research
Modality: Small Molecules, Gene Therapies

Overview

EG011 is an early-stage drug candidate developed by Ark Therapeutics, originating from foundational research collaborations with University College London and the AI Virtanen Institute in Finland. As of 2010, it was undergoing academic clinical studies for the treatment of refractory angina.

Brand names: Trinam
Other names: Ad-VEGF-DAdenoviral VEGF-D

Targets

WAS (Wiskott-Aldrich syndrome protein)

Beyond the preview

Go deeper on EG011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG011.

Explore the full profile